Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - HC Wainwright lowered their Q1 2024 EPS estimates for shares of Atossa Therapeutics in a note issued to investors on Tuesday, April 2nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.07) for the quarter, down from their previous forecast of ($0.06). HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Atossa Therapeutics' Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.31) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.29) EPS and FY2028 earnings at ($0.24) EPS.
Several other research firms have also weighed in on ATOS. Cantor Fitzgerald restated an "overweight" rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. StockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, March 18th.
Check Out Our Latest Report on Atossa Therapeutics
Atossa Therapeutics Price Performance
Shares of NASDAQ ATOS traded up $0.08 during trading on Thursday, hitting $2.10. The stock had a trading volume of 4,020,788 shares, compared to its average volume of 1,116,155. The company has a market capitalization of $263.13 million, a PE ratio of -8.75 and a beta of 1.20. The firm has a fifty day moving average of $1.22 and a two-hundred day moving average of $0.92. Atossa Therapeutics has a 12 month low of $0.59 and a 12 month high of $2.27.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Atossa Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $98,000. XTX Topco Ltd purchased a new position in shares of Atossa Therapeutics in the 2nd quarter worth about $50,000. Two Sigma Securities LLC purchased a new position in shares of Atossa Therapeutics in the 2nd quarter worth about $32,000. Renaissance Technologies LLC increased its holdings in Atossa Therapeutics by 14.7% in the 2nd quarter. Renaissance Technologies LLC now owns 1,074,070 shares of the company's stock worth $1,353,000 after buying an additional 138,000 shares in the last quarter. Finally, LPL Financial LLC bought a new stake in Atossa Therapeutics in the 2nd quarter worth about $59,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
